Digest Network Come funziona
Network
/
Società
PO
Non verificato

POXEL SA

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

17 comunicati stampa

Guarda tutti i comunicati
24/11/2025
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Sanità
POXEL SA: Update on the Proposed Recovery Plan and Organisation of a Webinar
Fonte
POXEL SA
Emittente
Business Wire
1.00
0
31/10/2025
Mercato del lavoro
Biotecnologia
Farmaceutica
Salute
Appointment of Yves Decadt as Member of Poxel’s Board of Directors
Fonte
POXEL SA
Emittente
Business Wire
1.00
0
01/08/2025
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Mercato del lavoro
Following the Filing for the Opening of Reorganization Proceedings, Poxel Announces Changes to Its Corporate Governance
Fonte
POXEL SA
Emittente
Business Wire
1.00
0
29/07/2025
Biotecnologia
Farmaceutica
Salute
Mercato del lavoro
Poxel Provides Update on Negotiations with Creditors and Announces Filing of Reorganization Proceedings, Upcoming Change of Corporate Governance and Suspension of Trading
Fonte
POXEL SA
Emittente
Business Wire
1.00
0
30/06/2025
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Poxel Announces Postponement of its Annual General Meeting and Provides a Corporate Update
Fonte
POXEL SA
Emittente
Business Wire
1.00
0
19/06/2025
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Poxel SA: New Scientific Presentations by Key Opinion Leaders to Further Highlight the Therapeutic Potential of Imeglimin at ADA 2025, the Leading Diabetes Conference
Fonte
POXEL SA
Emittente
Business Wire
1.00
0
28/05/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Eventi
New Clinical and Scientific Data on TWYMEEG® to be Presented at the 68th Annual Meeting of the Japan Diabetes Society
Fonte
POXEL SA
Emittente
Business Wire
1.00
0
26/05/2025
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Cardiologia
Eventi
Industria
Poxel Announces Positive Preclinical Data for PXL065 in Hypertrophic Cardiomyopathy To Be Presented at the ESC Congress 2025
Fonte
POXEL SA
Emittente
Business Wire
1.00
0
31/03/2025
Poxel Announces Grant of New Patent in Japan for the Use of Imeglimin in Type-2 Diabetic Patients with Renal Impairment
Fonte
POXEL SA
Emittente
Business Wire
1.00
0
20/03/2025
Industria
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Poxel Announces Positive Results from a Preclinical Study for PXL065, a Proprietary Deuterium-Stabilized R-Stereoisomer of Pioglitazone, in Hypertrophic Cardiomyopathy
Fonte
POXEL SA
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0